Mark White

LinkedIn Fam -- I don't know how we got this lucky, but we are EXTREMELY fortunate that Steven Moore has joined the HELIO team!! Those of you who know Steve will vouch that he brings an unbelievable energy and positivity to every relationship that he has. Steve will (obviously) help us with growing the Government Pricing practice, but he's a triple threat in that he can also assist us with our current suite of Compliance Consulting services AND -- what we think the future of Consulting will entail -- tech-enabled services across ALL areas. As I mentioned earlier this week, our plan is to tech-enable all areas of the Life Sciences industry. Steve will be crucial to continuing making that happen (check out our website for case studies of previous and current projects!). Ping one of us on the HELIO side if you want to understand how to apply GenAI technology to your current processes and operations to become more EFFICIENT and optimize your resources / team. I hope everyone has a great Holiday coming up and an amazing summer! #techenabledservices #genai

46

15 Comments

Hear directly from our CEO why CTB is the go to platform for clinical trial sponsors seeking efficiency and results. 🚀 CTB is providing smarter tools, faster results, and cost savings. 👉 Watch and follow us to see how CTB can make a difference for your company! #CTB #businessSolutions #clinicaltrials #efficiency #costsavings #tools #businessgrowth #innovation #success 

1

In #NeurodegenerativeDisease news, specifically on an experimental treatment for #ALS, with this new #strategic partnership is penned between Dewpoint Therapeutics and Mitsubishi Tanabe Pharma America. ⚛️ The asset is the former's drug, designed "to address the accumulation of a protein into toxic structures that lead to neuronal dysfunction in people with ALS." 🤝 The alliance would grant MTP exclusive rights to license, upon achieving certain developmental milestones. ⚕️ This would add to MTP's existing US-marketed ALS treatment, #Radicava https://lnkd.in/evayrVv4' #Dewpoint #Mitsubishi #Pharma #Biopharma #Healthcare

6

🔬 Advancing Oncology Research with Custom Assay Development and Validation 🔬 Attention Pharma Leaders in Oncology! In the rapidly evolving landscape of cancer research, having the right partner for custom assay development and validation is crucial to the success of your studies. At NeoGenomics, we specialize in providing comprehensive assay development and validation services across all technologies, ensuring your research achieves its full potential. Our expertise includes: ✅ Custom Assay Development: Tailored solutions to meet the unique demands of your oncology research, from biomarker discovery to companion diagnostics. ✅ Assay Validation: Rigorous validation processes to ensure accuracy, precision, and reproducibility, compliant with industry standards and regulatory requirements. ✅ Technological Versatility: Proficiency across a wide range of technologies, including NGS, IHC, flow cytometry, and more. ✅ Expert Consultation: Our team of seasoned scientists and industry experts are here to collaborate with you at every step, from initial concept to final implementation. Partner with us to leverage our cutting-edge facilities, innovative methodologies, and dedicated support. Together, we can accelerate your oncology research and bring groundbreaking therapies to patients faster. Let's discuss how we can support your next big breakthrough in oncology. I look forward to connecting with you! #Oncology #Pharma #CustomAssays #AssayDevelopment #AssayValidation #CancerResearch #Biomarkers #CompanionDiagnostics #CDx #NGS #PCR #FlowCytometry #IHC #ResearchSupport

4

It’s interesting that despite the abundance of competition and options in the U.S. (with far more biosimilars available for Humira than in Israel), we can still offer brand-name Humira at a price lower than the cheapest biosimilar option in the U.S. #biosimilars #ILMEDS #Humira

8

2 Comments

Looking forward to attending #ASH2024 this year. Let's connect and I can share with you how TD2 can support your next trial. 🔗https://hubs.li/Q02YXgqv0 #HematologyOncology #ClinicalTrials #OncologyCRO #BloodCancerResearch #DrugDevelopment #PrecisionOncology #ClinicalTrialSolutions

1

What could today's decision mean for biopharma? As former President Donald Trump returns to power The Associated Press projected his presidential victory Wednesday morning — the biopharma industry may see the door open wider for more dealmaking, with Lina Khan facing an exit at the Federal Trade Commission..... ...But Trump’s presumptive victory could also send shockwaves across the biopharma industry if his newly-appointed leaders at HHS or the FDA seek major reforms for their agencies under the “Make America Healthy Again” slogan.... https://lnkd.in/gsHjPa_t #Biopharma #HealthcarePolicy #FDA #LifeSciences #DrugPricing #PharmaDeals #BusinessDevelopment #RepublicanLeadership #USPolitics #FederalTradeCommission #InnovationEconomy #HealthcareReform #Investment #celltherapy #genetherapy #advancedtherapies #regenerativemedicine #biotech #biotechnology #lifescience #lifesciences #dealmaking #mergersandacquisitions #USHealthcare

18

6 Comments

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

Innovative life science therapies are a dime a dozen, but the ones accessible to patients will drive success. Knowing that drug prices are most patients' window into the industry, manufacturers and stakeholders must be involved in the pricing decisions, as they should be with every step of the commercialization continuum. Backing pricing with robust data and transparency strengthens go-to-market strategies and reinforces trust with payers, providers, and patients. By embedding transparency into our pricing and product value messaging, we create a stronger foundation for long-term success because bringing therapies to market with measurable value is no longer optional; it's expected. The recent lawsuit against major PBMs and insulin manufacturers underscores a critical lesson for the life sciences industry: transparency in pricing and value creation must be a cornerstone of commercialization. https://lnkd.in/eHRaJywB

14

1 Comment

#SABCS24 Following the FDA approval of Inavolisib, SABCS24 will showcase data on various PI3Ka inhibitors. After initial clinical data for RLY-2608 was presented in the September conference call and for STX-478 at ESMO24, updated Phase 1 data for both drugs will be shared at SABCS24. Although the clinical development of LOXO-783 was discontinued, SABCS24 will provide the first opportunity to review its clinical data. Additionally, the preclinical characterization of LY4045004, a new PI3Ka inhibitor being developed based on the lessons learned from the LOXO-783 program, will also be presented. Unlike the previously mentioned mutant-selective PI3Ka inhibitors, preclinical data will also be presented for BBO-10203, a PI3Ka:RAS interaction inhibitor. Recently, BBO-10203 was administered to the first patient in the Phase 1 BREAKER-101 study.

9

𝟗𝟎% 𝐨𝐟 𝐥𝐞𝐚𝐝𝐞𝐫𝐬 𝐚𝐫𝐞 𝐨𝐩𝐭𝐢𝐦𝐢𝐬𝐭𝐢𝐜 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐚𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. But what’s standing in the way of commercialization? While “payer and reimbursement challenges” remains the top force affecting the commercialization of advanced therapies in the next 12–18 months, this year it tied for the top position with “𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐝 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲,” underscoring a push toward consistency and lower cost of goods sold (COGS)… Thanks Daniella Kranjac! #deloitte #manufacturing #costofgoods #celltherapy #advancedtherapies #regenerativemedicine #optimism #commercialbarriers #costofgoods #manufacturingtechnology #improvedtechonology #biotech #biotechnology #lifesciences #lifescience #strategicinnovation #scalability #automation #operationalefficiencies https://lnkd.in/gHkPBD7w

30

2 Comments

📢 Pharmaceuticals Update 📢 Suven Pharmaceuticals is set to acquire a 56% stake in US-based NJ Bio Inc for USD 64.4 million. This strategic acquisition will strengthen Suven’s position as a leading technology-driven CDMO, specializing in antibody-drug conjugates (ADCs). NJ Bio's expertise and client base will significantly boost Suven's presence in the market. 🔻 Suven Pharmaceuticals Share Price: ₹1295.80 (-0.46%) Piramal Pharma will pay USD 407,400 to VetDC Inc. to settle a dispute over rejected product batches. Despite the payout, Piramal Pharma aims to minimize legal costs and maintain financial stability. 🔻 Piramal Pharma Share Price: ₹259.65 (-2.78%) Stay tuned for more updates in the pharmaceutical industry! #Pharmaceuticals #Acquisition #MarketNews #SuvenPharma #PiramalPharma #CDMO #ADC #BusinessUpdate

15

2 Comments

Led by Markus Renschler, MD, Light Horse Therapeutics has made significant progress in the oncology space with a $62M #SeriesA funding round led by MPM BioImpact and Omega Funds, alongside Novartis Venture Fund. This marks a big step for their work in developing LHT-001, a promising candidate targeting critical cancer pathways. In parallel, their partnership with Novartis could be worth up to $1B, combining Light Horse's innovative pipeline with Novartis' expertise in oncology drug development and commercialization. This collaboration has the potential to address unmet needs in cancer treatment and accelerate progress in this critical field. #Biotech #Oncology #Immunology #Innovation #LightHorseTherapeutics #Novartis #MPMBioImpact #OmegaFunds

7

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL   Learn more about….   👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others   The MSL Talk Podcast will be available Tuesday May 14th, 2024 on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers  

15

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

15

2 Comments

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

14

5 Comments

We started out Q1 with cautious optimism and the numbers continue to show the confidence was warranted. Biopharma M&A activity more than doubled nationally during the year’s first three months, coinciding with a rebound in venture capital deals as well as a flurry of IPOs. These are all good signs that the drug development cycle is normalizing and should translate into additional funding being available at the seed and Series A stages. Certain to be on the minds of funders and startups attending #AlignSummit24 on Thursday! https://lnkd.in/erEiJm6S  

112

5 Comments

  Propanc Biopharma, Inc. (OTCQB:PPCB) is dedicated to the development of PRP, a therapy based on pancreatic proenzymes aimed at preventing tumor recurrence and metastasis. As we move through the drug development pipeline, PRP has completed preclinical development and is now entering clinical phase with a Phase 1B, First-In-Human study in advanced cancer patients suffering from solid tumors.    Our approach focuses on a treatment that is effective for long-term use, suitable for patients diagnosed with cancer and potentially for those at high risk of developing cancer. Our commitment to providing an anti-cancer product that is both effective and well-tolerated underscores our response to the urgent need for better cancer treatments.   www.propanc.com   #propanc #ppcb #biopharma #cancer #oncology  

7